Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2017
Hypocalcaemia after denosumab in older people following fracture.
Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review.Endocrine journal · 2025Review
- Influence of loop diuretics on denosumab-induced hypocalcaemia in osteoporosis: a retrospective observational analysis.Journal of pharmaceutical health care and sciences · 2024Article
- Safety of In-hospital Parenteral Antiosteoporosis Therapy Following a Hip Fracture: A Retrospective Cohort.Journal of the Endocrine Society · 2024Article
- Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Article
- Tussilagone Inhibits Osteoclastogenesis and Periprosthetic Osteolysis by Suppressing the NF-κB and P38 MAPK Signaling Pathways.Frontiers in pharmacology · 2020Article
- Interaction among Calcium Diet Content, PTH (1-34) Treatment and Balance of Bone Homeostasis in Rat Model: The Trabecular Bone as Keystone.International journal of molecular sciences · 2019Article
- Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches.Stem cells international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypocalcaemia following denosumab therapy can be observed in older adults. This is more common if their pre-treatment corrected serum calcium concentrations are less than 2.28 mmol/L. Denosumab remains a safe treatment in older people but we recommend a cautious approach in people at risk.
introductionPrevious studies have indicated that denosumab, an anti-RANK ligand (RANKL) monoclonal antibody, for treatment of osteoporosis is well-tolerated. There is little data specifically regarding its adverse effect profile in a hospitalised older person. Primarily, this study wished to determine the frequency of hypocalcaemia following denosumab administration in older people admitted to hospital following fracture. Secondarily, this study wished to determine any associations that may predict the development of hypocalcaemia.
methodsThis was a prospective study of 33 participants using a paired study design aged 70 years old or more with fragility fractures who were given denosumab in a rehabilitation hospital in Sydney. The primary outcome was the frequency of hypocalcaemia. Hypocalcaemia was defined as corrected serum concentration of less than 2.20 mmol/L on day 14 after denosumab administration.
resultsOf the 33 participants with a mean age of 84.6 ± 1.2 years old, 5 participants (15.2 %) developed hypocalcaemia post injection. A paired t test showed a mean difference between the baseline and post injection calcium concentrations to be 0.059 mmol/L (95 %CI 0.020-0.098; t = 3.080, p = 0.004). Regression analysis showed that pre-denosumab serum calcium concentration correlated with the post-denosumab injection calcium concentration (R = 0.631, 95 %CI 0.288-0.977; p = 0.001). No other variables were significant. Further, a baseline serum calcium concentration of 2.28 mmol/L was able to predict post-denosumab hypocalcaemia with a sensitivity of 80 % and specificity of 86 %.
conclusionsDenosumab is a relatively safe treatment of osteoporosis. This study shows that hypocalcaemia following denosumab therapy can be observed in older adults. Clinicians should be aware of this adverse effect when using denosumab in the older people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.